# Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

> **NCT00206635** · — · COMPLETED · sponsor: **Bayer** · enrollment: 432 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Interferon beta-1b (Betaseron, BAY86-5046)

## Key facts

- **NCT ID:** NCT00206635
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 432 (ACTUAL)
- **Last updated:** 2012-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00206635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00206635, "Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00206635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*